The Critical Path Institute (C-Path) was founded in 2005 as an independent nonprofit organization through a collaborative effort between public and private sectors in alignment with the FDA’s Critical Path Initiative. C-Path is committed to spearheading partnerships that drive advancements in treatments for individuals globally. Widely respected for its role in hastening drug development, C-Path has formed multiple global consortia, programs, and endeavors, engaging over 1,600 experts and delegates from governmental and regulatory bodies, academic institutions, patient advocacy groups, disease foundations, and pharmaceutical and biotechnology firms.